62 results
8-K
EX-99.1
AXSM
Axsome Therapeutics Inc
20 Feb 24
Corporate Presentation February 2024
4:30pm
death in the U.S.1 AXS-05 represents a potentially new mechanism of action for smoking cessation Positive FDA Pre-IND meeting guidance received from
8-K
EX-99.1
AXSM
Axsome Therapeutics Inc
8 Jan 24
Corporate Presentation January 2024
7:10am
(4 weeks) 1:1 Randomization Follow up (1 Weeks) Baseline AXS-05
Smoking is single largest cause of preventable death in the U.S.1 70% of smokers
8-K
EX-99.1
fr68ydjoo9ztoeek
4 Jan 24
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
7:11am
8-K
EX-99.1
7v7 f8kten62qnxzl
15 Aug 23
Corporate Presentation August 2023
7:45am
8-K
EX-1.1
8b9x6dtt4gem 7y
28 Jun 23
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
7:50pm
8-K
EX-99.1
c8j9vc60jbat kv3x
13 Jun 23
Financial Statements and Exhibits
5:22pm
8-K
EX-10.1
ceh4k5g0w980qm3jl4
8 Jun 23
Departure of Directors or Certain Officers
5:02pm
8-K
EX-99.1
6nnxvve044jhm9azhm
28 Nov 22
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
7:07am
8-K
EX-99.1
8kur6xlo0 195r
3 Oct 22
Other Events
7:09am
8-K
EX-99.1
ablkwy2ki0b
9 May 22
Completion of Acquisition or Disposition of Assets
7:05am
8-K
EX-99.1
uad6m78jijhl8shrraqy
28 Mar 22
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
8:00am